SYSTEM AND METHOD FOR USING A DYNAMIC GAMMA KNIFE FOR RADIOSURGERY
    131.
    发明公开
    SYSTEM AND METHOD FOR USING A DYNAMIC GAMMA KNIFE FOR RADIOSURGERY 有权
    SYSTEM UND VERFAHREN ZUR VERWENDUNG EINES DYNAMISCHEN GAMMAMESSERS in DER RADIOCHIRURGIE

    公开(公告)号:EP2278933A4

    公开(公告)日:2017-08-09

    申请号:EP09742997

    申请日:2009-05-04

    Applicant: STC UNM

    Abstract: The present invention is a method and system for developing a dynamic scheme for Gamma Knife radiosurgery based on the concept of "dose-painting" to take advantage of robotic patient positioning systems on the Gamma Knife C and Perfexion units. The spherical high dose volume created by the Gamma Knife unit will be viewed as a 3D spherical "paintbrush", and treatment planning is reduced to finding the best route of this "paintbrush" to "paint" a 3D tumor volume. Under the dose-painting concept, Gamma Knife radiosurgery becomes dynamic, where the patient is moving continuously under the robotic positioning system.

    Abstract translation: 本发明是基于“剂量绘画”概念开发用于伽玛刀放射手术的动态方案以利用伽马刀C和Perfexion单元上的机器人患者定位系统的方法和系统。 由伽玛刀单元创建的球形高剂量体积将被视为3D球形“画笔”,并且治疗计划被缩减为找到该“画笔”来“绘制”3D肿瘤体积的最佳路线。 在剂量绘画的概念下,伽玛刀放射手术变得动态,患者在机器人定位系统下持续移动。

    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA
    139.
    发明公开
    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA 审中-公开
    抑制巨噬细胞,C反应蛋白和免疫治疗系统性红斑狼疮和血小板减少性紫癜

    公开(公告)号:EP2097087A4

    公开(公告)日:2013-01-02

    申请号:EP07867365

    申请日:2007-11-06

    Applicant: STC UNM

    CPC classification number: A61K35/15 A61K35/28 A61K38/1745 A61K2300/00

    Abstract: The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

Patent Agency Ranking